Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter for “Longleaf Partners Global Fund”. A copy of the letter can be downloaded here. The Fund returned 5.27% in the quarter, compared to the MSCI World’s 3.12 % and the MSCI World Value’s 3.34% return. The Fund returned 16.72% for the year, compared to 21.09% and 20.79% returns, respectively, for the indexes. 2025 was a solid year for the Fund, celebrating Southeastern's 50th anniversary and the 25th ...

Core Insights - BIO-key International, Inc. has secured a $1.04 million license renewal and expansion order from a foreign retail bank, marking a 30% increase over the previous year's renewal value [1] - The bank's biometric identification technology has grown from 7 million enrolled clients in 2015 to over 30 million today, managing more than 300 million fingerprints [4] - The company reported a year-end cash position of $2.7 million, indicating sufficient cash and anticipated inflows to support growth plans [2][3] Company Developments - The renewal order reflects the customer's ongoing expansion of the biometric solution deployment [1] - Approximately 10,000 bank employees utilize BIO-key's fingerprint technology for authentication, enhancing security and reducing unauthorized activity [5] - The biometric system supports the bank's know-your-customer (KYC) processes, ensuring strong identity verification and trust [5] Industry Trends - Identity assurance is becoming crucial for modern banking, especially as operations become more automated and AI-assisted [6] - The demand for robust systems to authenticate customer interactions is increasing, highlighting the importance of biometric solutions in the banking sector [6] - BIO-key's scalable biometric platform has supported significant growth for its customer over the past decade, indicating a trend towards biometric-centric identity management [6]

Core Insights - The international operations of Bio-Rad Laboratories are crucial for assessing its financial resilience and growth prospects, especially given its expansive global footprint [1][2] Group 1: International Revenue Performance - Bio-Rad's total revenue for the quarter was $693.2 million, reflecting a year-over-year increase of 3.9% [4] - Asia generated $161.8 million in revenue, accounting for 23.3% of total revenue, which was a slight surprise of +0.01% compared to the projected $161.79 million [5] - EMEA contributed $242.6 million, representing 35% of total revenue, exceeding the consensus estimate of $221.09 million by +9.73% [6] Group 2: Future Revenue Projections - For the current fiscal quarter, analysts expect Bio-Rad to achieve revenues of $605 million, a 3.4% increase from the same quarter last year, with contributions of 20% from Asia ($121.03 million) and 32.1% from EMEA ($194.26 million) [7] - The full-year revenue projection stands at $2.59 billion, indicating a 0.2% rise from the previous year, with Asia expected to contribute 21.4% ($555.2 million) and EMEA 32.3% ($837.23 million) [8] Group 3: Market Dynamics and Stock Performance - The reliance on international markets presents both opportunities and challenges for Bio-Rad, necessitating close monitoring of international revenue trends to forecast future directions [9] - The stock has experienced a decline of 10.9% over the past month, contrasting with a 0.8% decrease in the S&P 500, and a 16.9% decrease over the past three months compared to a 4.3% increase in the S&P 500 [13]

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that by 2040, humanoid robots could create a market worth $250 trillion, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4][6] - Prominent figures in technology and investment, including Bill Gates and Warren Buffett, recognize AI as a significant advancement with the potential for substantial social benefits [8]

Key Takeaways BIO posted Q4 adjusted EPS of $2.51, missing estimates as shares sank 12.3%. BIO revenues rose 3.8% to $693.2M, led by Clinical Diagnostics growth of 8.4%. BIO guided 2026 currency-neutral revenue growth of 0.5-1.5% with 12-12.5% margin outlook.Bio-Rad Laboratories, Inc. (BIO) posted fourth-quarter 2025 adjusted earnings per share (EPS) of $2.51, which missed the Zacks Consensus Estimate by 2.3%. The bottom line decreased 13.4% from the prior-year quarter’s level.The quarter’s adjustments prim ...

Financial Performance - Bio-Rad's Life Science segment generated approximately 40% of consolidated net sales, while the Clinical Diagnostics segment accounted for 60% for the year ended December 31, 2025[9]. - The estimated worldwide sales for Life Science products are approximately $19 billion, with principal customers including universities, government agencies, and pharmaceutical manufacturers[10]. - The Clinical Diagnostics segment's estimated worldwide sales are approximately $16 billion, supporting over 300 clinical diagnostic tests[12]. Workforce and Operations - Bio-Rad employs approximately 770 sales personnel globally, enhancing customer engagement and long-term relationships[18]. - The company had approximately 790 employees focused on research and development as of December 31, 2025, indicating a strong commitment to innovation[25]. - Bio-Rad operates in over 36 countries, with approximately 40% of sales generated from the U.S. and 60% from international markets, primarily Europe[8][9]. - Bio-Rad's workforce consists of approximately 7,450 employees, with 46% located in the Americas, 36% in Europe, and 18% in Asia Pacific[35]. Intellectual Property - The company holds over 2,100 U.S. and international patents, emphasizing its focus on intellectual property as a valuable asset[16]. Regulatory Compliance - The company is subject to various regulatory requirements, including compliance with FDA regulations for its diagnostic products[26][30]. Revenue Model - Bio-Rad's clinical diagnostics portfolio generates recurring revenue through ongoing sales of test kits and consumables, indicating a stable revenue model[13]. Investment and Financial Position - As of December 31, 2025, the fair value of the company's investment in Sartorius was $5,669.2 million, representing approximately 38% of the outstanding ordinary shares and 28% of the preference shares[40]. - Sartorius reported sales revenue of €3,380.7 million and a net profit of €137.4 million for the year ended December 31, 2024[42]. - The company's cash flow from operating activities for Sartorius was €976.2 million, while cash flow from investing activities was negative at €(425.8) million[42]. - The company had $1.20 billion in principal amount of fixed-rate long-term debt outstanding as of December 31, 2025[176]. - Sartorius's total current assets were €2,113.7 million and total non-current assets were €7,989.3 million as of December 31, 2024[42]. - The company's equity as of December 31, 2024, was reported at €3,897.8 million[42]. Foreign Currency and Interest Rate Risks - A hypothetical 10% depreciation/appreciation of foreign currencies relative to the U.S. dollar would result in an unrealized gain/loss of $59.9 million on the company's derivative position as of December 31, 2025[174]. - A 10% depreciation/appreciation on the quoted stock prices for Sartorius shares at December 31, 2025, would result in an approximate loss/gain of $566.9 million reported in the financial statements[177]. - The company centrally manages foreign currency exposures and uses forward contracts to hedge against foreign exchange risks[172]. - Interest rate changes could impact the fair value of the company's fixed-income investment portfolio, with a hypothetical increase or decrease in interest rates by 50 and 100 basis points resulting in a change of approximately $9.9 million and $20.0 million, respectively[175].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Viewpoint - Bio-Rad Laboratories reported quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share, and down from $2.9 per share a year ago [1] Financial Performance - The earnings surprise for the quarter was -2.34%, with the company previously expected to post earnings of $2.3 per share but actually reporting $2.26, resulting in a surprise of -1.74% [2] - Bio-Rad's revenues for the quarter were $693.2 million, slightly surpassing the Zacks Consensus Estimate by 0.01%, and up from $667.5 million year-over-year [3] - Over the last four quarters, the company has exceeded consensus revenue estimates three times [3] Stock Performance - Bio-Rad shares have declined approximately 3.1% since the beginning of the year, while the S&P 500 has gained 1.4% [4] - The current Zacks Rank for Bio-Rad is 3 (Hold), indicating expected performance in line with the market in the near future [7] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.79 on revenues of $605 million, and for the current fiscal year, it is $10.36 on revenues of $2.64 billion [8] - The trend of estimate revisions for Bio-Rad was mixed ahead of the earnings release, which could change following the recent report [7] Industry Context - The Medical - Products industry, to which Bio-Rad belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [9] - Agilent Technologies, another company in the same industry, is expected to report quarterly earnings of $1.37 per share, reflecting a year-over-year increase of 4.6% [10]

Financial Data and Key Metrics Changes - Net sales for Q4 2025 were approximately $693 million, a 3.9% increase from $668 million in Q4 2024. On a currency neutral basis, this represents a 1.7% year-over-year increase driven by the clinical diagnostics segment [11] - Full year net sales for 2025 were $2.583 billion, a 0.7% increase from $2.567 billion in 2024. On a currency neutral basis, sales were essentially flat compared to 2024 [17] - Q4 GAAP gross margin was 49.8%, down from 51.2% in Q4 2024. Non-GAAP gross margin was 52.5%, compared to 53.9% in the previous year [13][14] - Full year non-GAAP gross margin was 53.3%, down from 55% in 2024, primarily due to reduced fixed manufacturing absorption and higher material costs [19] Business Segment Data and Key Metrics Changes - Clinical diagnostics segment sales in Q4 2025 were approximately $425 million, an 8.4% increase from $393 million in Q4 2024, driven by higher sales of quality control and blood typing products [13] - Life science segment sales in Q4 2025 were $268 million, a 2.6% decrease from $275 million in Q4 2024, attributed to a constrained academic research and biotech funding environment [11] - The ddPCR portfolio posted mid-single-digit year-over-year growth in Q4, driven by the success of the QX700 platform [12][7] Market Data and Key Metrics Changes - Currency neutral sales decreased in the Americas, partially offset by increased sales in EMEA and Asia Pacific [12] - In biopharma, funding conditions improved in the second half of 2025, with expectations for a modest recovery in 2026 [9] - Cautious spending persisted in academia and government, impacting instrument demand [8] Company Strategy and Development Direction - The company plans to advance several product launches in 2026, including an IVD version of the QX600 and additional high-value ddPCR assays [10] - Focus on disciplined innovation is central to the long-term growth strategy, with an emphasis on operational performance and margin expansion [10][31] - The company is actively looking for additional assets to accelerate top-line growth and margin expansion [30] Management's Comments on Operating Environment and Future Outlook - Management noted early signs of stabilization across core markets, with improvements in NIH funding and biopharma funding [28] - The company remains focused on driving long-term value and is seeing the impact of a performance-related approach [29] - Management expressed confidence that actions taken will translate into improved financial results over time [10] Other Important Information - Free cash flow for Q4 2025 was $119 million, compared to $81 million in Q4 2024. Full year free cash flow improved to approximately $375 million versus $290 million in 2024 [23] - The company retired 1.2 million shares through its buyback program at a total cost of approximately $296 million during 2025 [23] Q&A Session Summary Question: About the ddPCR business growth - Management indicated that the strong quarterly growth was driven by the QX700 platform and the conversion of qPCR applications to ddPCR, with ongoing reagents being a significant part of the portfolio [34][35] Question: Process chromatography changes - Management explained that recent changes in vaccine production strategies impacted demand, leading to a conservative outlook for the process chromatography segment [37][38] Question: Operating margins outlook - Management acknowledged the impact of process chromatography on operating margins and indicated that while some costs from Q4 are not expected to recur, they are being realistic in their guidance [39][40] Question: Clinical diagnostics growth - Management attributed muted growth in clinical diagnostics to a mix of portfolio performance and geographic factors, particularly reliance on China [58][59] Question: Buyback strategy - Management clarified that the lack of buybacks in Q4 does not signal any specific strategy, as they are looking at opportunities opportunistically [63][64]

Financial Data and Key Metrics Changes - In Q4 2025, net sales were approximately $693 million, a 3.9% increase from $668 million in Q4 2024. On a currency neutral basis, this represents a 1.7% year-over-year increase [11] - Full year 2025 net sales were $2.583 billion, a 0.7% increase from $2.567 billion in 2024. On a currency neutral basis, sales were essentially flat compared to 2024 [17][18] - Q4 GAAP gross margin was 49.8%, down from 51.2% in Q4 2024. Non-GAAP gross margin was 52.5%, compared to 53.9% in the previous year [13][14] - Full year non-GAAP gross margin was 53.3%, down from 55% in 2024, primarily due to reduced fixed manufacturing absorption and higher material costs [19] Business Segment Data and Key Metrics Changes - Clinical diagnostics segment sales in Q4 2025 were approximately $425 million, an 8.4% increase from $393 million in Q4 2024, driven by higher sales of quality control and blood typing products [13] - Life science segment sales in Q4 2025 were $268 million, a 2.6% decrease from $275 million in Q4 2024, impacted by constrained academic research and biotech funding [11][12] - The ddPCR portfolio posted mid-single-digit year-over-year growth in Q4, driven by the success of the QX700 platform [12][26] Market Data and Key Metrics Changes - Currency neutral sales decreased in the Americas, partially offset by increased sales in EMEA and Asia Pacific [12][18] - In biopharma, funding conditions improved in the second half of 2025, with expectations for a modest recovery in 2026 [9] - Cautious spending persisted in academia and government, affecting instrument demand [8] Company Strategy and Development Direction - The company plans to advance several product launches in 2026, including an IVD version of the QX600 and additional high-value ddPCR assays [10] - Focus on disciplined innovation is central to the long-term growth strategy, with an emphasis on operational performance and cost structure management [10][31] - The company is actively looking for additional assets to accelerate top-line growth and margin expansion [30] Management's Comments on Operating Environment and Future Outlook - Management sees early signs of stabilization across core markets, with improvements in NIH funding and biopharma funding [28] - The company remains focused on driving long-term value and is witnessing the impact of a performance-related approach [29] - Management is optimistic about the growth potential of the ddPCR business and the overall diagnostics segment [28][29] Other Important Information - Free cash flow for 2025 was approximately $375 million, representing a conversion ratio of 138% for free cash flow to non-GAAP net income [23] - The company retired 1.2 million shares through its buyback program at a total cost of approximately $296 million during 2025 [23][24] - Non-GAAP guidance for 2026 anticipates currency neutral revenue growth between 0.5% and 1.5% [24] Q&A Session Summary Question: About the ddPCR business growth - Management noted strong quarterly growth in the ddPCR business, driven by the QX700 platform and ongoing reagent sales from a large installed base [34][35] Question: Process Chromatography changes - Management explained that recent changes in vaccine production strategies impacted the Process Chromatography forecast, leading to a conservative outlook [37][38] Question: Operating margins outlook - Management provided insights on the operating margin forecast, highlighting the impact of Process Chromatography and Q4 costs that are not expected to recur [39][40] Question: Clinical diagnostics growth - Management discussed the muted growth in clinical diagnostics, attributing it to a mix of product performance and geographic factors [57][59] Question: Buyback strategy - Management clarified that the lack of buybacks in Q4 does not signal any specific strategy, as they are actively looking for acquisition opportunities [63][64]